Indian Pharma market sees 6.9% growth in May: Report
New Delhi: The India pharmaceutical market (IPM) registered a 6.9 percent (on-year) growth in May, primarily propelled by strong performances in cardiac, respiratory, and anti-diabetes therapies, according to a report released by Motilal Oswal Financial Services Ltd.
Indian companies grew by 6.6%, while multinational corporations (MNCs) posted a higher 8.4% growth YOY in May. The acute therapy growth remained muted at 5% in May, marking the second consecutive month of subdued YoY performance.
For the 12 months ending in May, IPM growth was led by price/new launches/volume growth of 4.2 per cent/2.3 per cent/1.1 per cent YoY, IANS reported.
As of May, the Indian pharma companies held a majority share of 83 per cent in IPM, with the remaining held by multi-national pharma companies (MNCs).
In May, among the top 20 pharma companies, JB Chem (up 11.6 per cent YoY), Glenmark (up 11.8 per cent YoY), and Ajanta (up 10.6 per cent YoY) recorded higher growth rates vs IPM.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.